Skip to main content
CVE:ABCN

VIVO Cannabis Competitors

C$1.32
+0.07 (+5.60 %)
(As of 08/3/2018)
Add
Compare
Today's Range
C$1.27
C$1.33
50-Day Range
C$1.32
C$1.32
52-Week Range
C$0.80
C$4.06
Volume310,601 shs
Average Volume1.51 million shs
Market CapitalizationC$256.62 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

VIVO Cannabis (CVE:ABCN) Vs. CHV, PREV, COM, MYM, CURE, and HALO

Should you be buying ABCN stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to VIVO Cannabis, including (CHV) (CHV), (PREV) (PREV), 138267 (COM.TO) (COM), 17031 (MYM), Direxion Daily Healthcare Bull 3X Shares (CURE), and Halozyme Therapeutics (HALO).

(CHV) (CNSX:CHV) and VIVO Cannabis (CVE:ABCN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.

Earnings & Valuation

This table compares (CHV) and VIVO Cannabis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(CHV)N/AN/AN/AN/AN/A
VIVO CannabisN/AN/AN/AN/AN/A

Profitability

This table compares (CHV) and VIVO Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(CHV)N/AN/AN/A
VIVO CannabisN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for (CHV) and VIVO Cannabis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(CHV)0000N/A
VIVO Cannabis0000N/A

(PREV) (CNSX:PREV) and VIVO Cannabis (CVE:ABCN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.

Earnings & Valuation

This table compares (PREV) and VIVO Cannabis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(PREV)N/AN/AN/AN/AN/A
VIVO CannabisN/AN/AN/AN/AN/A

Profitability

This table compares (PREV) and VIVO Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(PREV)N/AN/AN/A
VIVO CannabisN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for (PREV) and VIVO Cannabis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(PREV)0000N/A
VIVO Cannabis0000N/A

138267 (COM.TO) (TSE:COM) and VIVO Cannabis (CVE:ABCN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.

Earnings & Valuation

This table compares 138267 (COM.TO) and VIVO Cannabis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
138267 (COM.TO)N/AN/AN/AN/AN/A
VIVO CannabisN/AN/AN/AN/AN/A

Profitability

This table compares 138267 (COM.TO) and VIVO Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
138267 (COM.TO)N/AN/AN/A
VIVO CannabisN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for 138267 (COM.TO) and VIVO Cannabis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
138267 (COM.TO)0000N/A
VIVO Cannabis0000N/A

17031 (CNSX:MYM) and VIVO Cannabis (CVE:ABCN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Earnings and Valuation

This table compares 17031 and VIVO Cannabis' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
17031N/AN/AN/AN/AN/A
VIVO CannabisN/AN/AN/AN/AN/A

Profitability

This table compares 17031 and VIVO Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
17031N/AN/AN/A
VIVO CannabisN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for 17031 and VIVO Cannabis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
170310000N/A
VIVO Cannabis0000N/A

Direxion Daily Healthcare Bull 3X Shares (CNSX:CURE) and VIVO Cannabis (CVE:ABCN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Direxion Daily Healthcare Bull 3X Shares and VIVO Cannabis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Direxion Daily Healthcare Bull 3X Shares0000N/A
VIVO Cannabis0000N/A

Earnings and Valuation

This table compares Direxion Daily Healthcare Bull 3X Shares and VIVO Cannabis' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Direxion Daily Healthcare Bull 3X SharesN/AN/AN/AN/AN/A
VIVO CannabisN/AN/AN/AN/AN/A

Profitability

This table compares Direxion Daily Healthcare Bull 3X Shares and VIVO Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Direxion Daily Healthcare Bull 3X SharesN/AN/AN/A
VIVO CannabisN/AN/AN/A

VIVO Cannabis (CVE:ABCN) and Halozyme Therapeutics (NEO:HALO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for VIVO Cannabis and Halozyme Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VIVO Cannabis0000N/A
Halozyme Therapeutics00014.00

Halozyme Therapeutics has a consensus price target of C$0.24, indicating a potential downside of 99.44%. Given Halozyme Therapeutics' higher possible upside, analysts clearly believe Halozyme Therapeutics is more favorable than VIVO Cannabis.

Valuation and Earnings

This table compares VIVO Cannabis and Halozyme Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVO CannabisN/AN/AN/AN/AN/A
Halozyme TherapeuticsC$267.59 million22.75C$130.40 millionC$0.9146.68

Halozyme Therapeutics has higher revenue and earnings than VIVO Cannabis.

Profitability

This table compares VIVO Cannabis and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VIVO CannabisN/AN/AN/A
Halozyme TherapeuticsN/AN/AN/A

Summary

Halozyme Therapeutics beats VIVO Cannabis on 3 of the 3 factors compared between the two stocks.


VIVO Cannabis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
HALO
Halozyme Therapeutics
1.3$42.48+0.5%C$0.00C$267.59 million46.68News Coverage
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Up
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49+6.3%C$0.00N/A0.00High Trading Volume
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.